For FDA, An NME Advisory Committee Extravaganza?
The beginning of 2008 could mark a significant shift in the way FDA reviews applications. A provision included in the FDA Amendments Act specifies that FDA shall either refer each NME to an advisory committee for review or provide in the action letter a summary of the reasons why it did not refer the product - and there is some indication that the agency is taking the former route.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth